Oral contraceptives and thromboembolic disease. Swedish experience.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001789:Blood Group Antigens; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003718:Denmark; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D008234:Lynestrenol / Q000009:adverse effects; D008297:Male; D008656:Mestranol / Q000009:adverse effects; D009203:Myocardial Infarction / Q000401:mortality; D009640:Norethindrone / Q000009:adverse effects; D013548:Sweden; D013923:Thromboembolism / Q000139:chemically induced* / Q000401:mortality; D013924:Thrombophlebitis / Q000453:epidemiology / Q000401:mortality; D013927:Thrombosis / Q000401:mortality; D013997:Time Factors; D006113:United Kingdom; D014481:United States
D001789:Blood Group Antigens; D003276:Contraceptives, Oral; D004997:Ethinyl Estradiol; D008656:Mestranol; D008234:Lynestrenol; D009640:Norethindrone